Cargando…
Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim
BACKGROUND: Obatoclax is a clinical stage drug candidate that has been proposed to target and inhibit prosurvival members of the Bcl-2 family, and thereby contribute to cancer cell lethality. The insolubility of this compound, however, has precluded the use of many classical drug-target interaction...
Autores principales: | Nguyen, Mai, Cencic, Regina, Ertel, Franziska, Bernier, Cynthia, Pelletier, Jerry, Roulston, Anne, Silvius, John R., Shore, Gordon C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522062/ https://www.ncbi.nlm.nih.gov/pubmed/26231047 http://dx.doi.org/10.1186/s12885-015-1582-5 |
Ejemplares similares
-
Cyclic Marinopyrrole Derivatives as Disruptors of Mcl-1 and Bcl-x(L) Binding to Bim
por: Cheng, Chunwei, et al.
Publicado: (2014) -
The NOXA–MCL1–BIM axis defines lifespan on extended mitotic arrest
por: Haschka, Manuel D., et al.
Publicado: (2015) -
Marinopyrrole Derivatives with Sulfide Spacers as Selective Disruptors of Mcl-1 Binding to Pro-Apoptotic Protein Bim
por: Cheng, Chunwei, et al.
Publicado: (2014) -
Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax
por: Bajpai, R, et al.
Publicado: (2015) -
A novel Mcl1 variant inhibits apoptosis via increased Bim sequestration
por: Hagenbuchner, Judith, et al.
Publicado: (2013)